Spyre Therapeutics (SYRE) Common Equity (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Common Equity came in at $670.8 million in Q1 2026, up 39.0% YoY from $482.6 million in Q1 2025, and down 6.21% on a QoQ basis from $715.2 million in Q4 2025.
Spyre Therapeutics (SYRE) Common Equity (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Common Equity data on file, last reported at $670.8 million in Q1 2026.
- Quarterly Common Equity rose 39.0% year-over-year to $670.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $670.8 million (up 39.0% YoY) and the FY2025 annual result came in at $715.2 million, up 38.13% from the prior year.
- Common Equity retreated to $670.8 million in Q1 2026, from $715.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $715.2 million in Q4 2025 to a low of -$245.4 million in Q3 2023.
- A 5-year average of $245.9 million and a median of $184.0 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity plunged 463.26% — and 2024, when it surged 352.48%.
- Tracing SYRE's Common Equity over 5 years: stood at $50.3 million in 2022, then soared by 265.8% to $184.0 million in 2023, then soared by 181.39% to $517.8 million in 2024, then jumped by 38.13% to $715.2 million in 2025, then fell by 6.21% to $670.8 million in 2026.
- The last three Common Equity figures came in at $670.8 million (Q1 2026), $715.2 million (Q4 2025), and $455.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | 1.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Bn |
| Mar 31, 2026 | 670.81 Mn |
| Dec 31, 2025 | 715.24 Mn |
| Sep 30, 2025 | 455.10 Mn |
| Jun 30, 2025 | 455.77 Mn |
| Mar 31, 2025 | 482.61 Mn |
| Dec 31, 2024 | 517.80 Mn |
| Sep 30, 2024 | 327.39 Mn |
| Jun 30, 2024 | 374.39 Mn |
| Mar 31, 2024 | 152.27 Mn |
| Dec 31, 2023 | 184.02 Mn |
| Sep 30, 2023 | -245.40 Mn |
| Jun 30, 2023 | -207.37 Mn |
| Mar 31, 2023 | 33.65 Mn |
| Dec 31, 2022 | 50.31 Mn |
| Sep 30, 2022 | 67.56 Mn |
| Jun 30, 2022 | 84.16 Mn |
| Mar 31, 2022 | 61.66 Mn |
| Dec 31, 2021 | 83.94 Mn |
| Sep 30, 2021 | 102.08 Mn |